Loading clinical trials...
Loading clinical trials...
Deciphering Metacognition and Treatment Response in Depression With a Novel Digital Paradigm
To develop and test a neurocomputational model of ketamine treatment response predictions in TRD.
The investigators propose applying a previously validated computational model of the MMN and the ensuing effects of NMDAR antagonism to predict treatment response following ketamine infusions in TRD patients and distinguish ketamine's antisuicidal effects from those related to mood improvements. The study has two subgoals: first, the computational mechanisms underlying MMN reductions that predict ketamine treatment response in TRD patients will be examined. Second, the computational mechanisms will be linked to their underlying neural causes using neural circuit models. Beyond understanding ketamine's short- and long-term mechanisms of action in TRD, the parameters obtained from fitting these models to noninvasive EEG recordings may facilitate single-patient treatment predictions. If successful, this approach may provide clinically useful prognostic statements in individual patients.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
St. Michael's Hospital
Toronto, Ontario, Canada
Start Date
October 3, 2022
Primary Completion Date
October 1, 2024
Completion Date
December 1, 2024
Last Updated
November 29, 2023
30
ESTIMATED participants
Ketamine
DRUG
Lead Sponsor
Unity Health Toronto
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions